Pacira BioSciences Announced Transfer or Voluntary Withdrawal of Listing
Pacira BioSciences (PCRX) notified Nasdaq of its intent to delist shares and deregister under Section 12(b) following its merger with Viatris. The company also plans to terminate registration under Section 12(g) and suspend reporting obligations.
How this was made

The 30-second read
Why it matters
A Nasdaq trading halt plus delisting/deregistration steps can quickly change liquidity, spreads, and eligibility for certain funds, increasing volatility around the filings and any shareholder conversion mechanics.
Market read
This is a company-specific corporate status change that can affect tradability immediately and may drive a sharp repricing due to delisting and reporting termination risk.
What to watch
Traders should verify whether shareholders receive cash or exchange into Viatris-related consideration, and whether any alternative trading venue exists before assuming permanent liquidity loss.
Background
The company says it completed its merger with Viatris and is moving to delist and deregister its shares, including filing Form 25 and intending Form 15 to end Exchange Act reporting.
Ticker impact
Pacira BioSciences notified Nasdaq after completing its merger with Viatris, requesting a trading halt and Form 25 delisting/deregistration.
Likely downside pressure as the market prices reduced liquidity and the path to delisting.
The article describes a direct Nasdaq delisting request (Form 25) and Exchange Act reporting termination intent, which typically increases trading risk and reduces institutional accessibility.
Market effects
Limited spillover, but it highlights heightened delisting risk for small/mid-cap biopharma post-merger structures.
Primarily US market microstructure impact via Nasdaq halt/delisting mechanics.
Low, as the event is US listing and SEC reporting related.
Counterpoint
If the merger structure provides an alternative listing or a clear post-merger trading venue, the delisting may be largely administrative and the stock could stabilize after mechanics settle.
Key entities
- companyPacira BioSciences
Subject issuer requesting Nasdaq trading halt and Form 25 delisting after merger completion.
- companyViatris
Counterparty referenced as the merger partner that Pacira says it completed with.
- venueNasdaq
Exchange notified by Pacira in connection with the requested trading halt and delisting process.
- regulatorSEC
Pacira references SEC forms (Form 25 and intended Form 15) to delist and terminate reporting.

